CRISPR Therapeutics’ (CRSP) Market Outperform Rating Reiterated at Citizens Jmp

Citizens Jmp reissued their market outperform rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research note released on Monday,Benzinga reports. Citizens Jmp currently has a $80.00 price target on the stock.

CRSP has been the subject of a number of other reports. Needham & Company LLC reissued a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Friday, July 17th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $55.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. UBS Group set a $80.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 12th. Finally, Evercore reissued an “outperform” rating and set a $76.00 target price on shares of CRISPR Therapeutics in a research note on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $68.06.

CRISPR Therapeutics Stock Up 0.2%

CRSP opened at $56.92 on Monday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85. The company has a market capitalization of $5.50 billion, a PE ratio of -11.96 and a beta of 1.76. The stock’s fifty day moving average is $53.80 and its 200-day moving average is $52.90. CRISPR Therapeutics has a one year low of $44.12 and a one year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. The firm had revenue of $10.18 million for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. On average, equities analysts predict that CRISPR Therapeutics will post -4.47 EPS for the current fiscal year.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc lifted its holdings in shares of CRISPR Therapeutics by 175.1% during the second quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock valued at $25,000 after purchasing an additional 296 shares during the last quarter. Mcguire Capital Advisors Inc. purchased a new position in CRISPR Therapeutics in the 4th quarter worth about $25,000. Ramirez Asset Management Inc. purchased a new position in CRISPR Therapeutics in the 4th quarter worth about $26,000. Rothschild Investment LLC increased its stake in CRISPR Therapeutics by 836.7% in the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after purchasing an additional 502 shares in the last quarter. Finally, Strategic Wealth Investment Group LLC acquired a new stake in CRISPR Therapeutics during the 2nd quarter worth about $36,000. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.